Simplify Asset Management Inc. Sells 2,018 Shares of AbbVie Inc. $ABBV

Simplify Asset Management Inc. decreased its stake in AbbVie Inc. (NYSE:ABBV) by 9.9% in the second quarter, Holdings Channel.com reports. The firm owned 18,384 shares of the company’s stock after selling 2,018 shares during the period. Simplify Asset Management Inc.’s holdings in AbbVie were worth $3,412,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Marshall & Sullivan Inc. WA bought a new position in AbbVie during the 2nd quarter valued at about $25,000. TD Capital Management LLC grew its stake in shares of AbbVie by 82.9% during the first quarter. TD Capital Management LLC now owns 128 shares of the company’s stock valued at $27,000 after buying an additional 58 shares during the last quarter. Spurstone Advisory Services LLC bought a new stake in shares of AbbVie during the 2nd quarter worth approximately $28,000. Cypress Capital Management LLC WY purchased a new position in AbbVie during the 1st quarter valued at $35,000. Finally, Bear Mountain Capital Inc. grew its position in AbbVie by 480.6% in the 2nd quarter. Bear Mountain Capital Inc. now owns 209 shares of the company’s stock valued at $40,000 after acquiring an additional 173 shares during the last quarter. 70.23% of the stock is currently owned by institutional investors.

AbbVie Trading Down 0.4%

NYSE:ABBV opened at $218.31 on Tuesday. The stock has a market capitalization of $385.84 billion, a price-to-earnings ratio of 103.96, a PEG ratio of 1.42 and a beta of 0.50. AbbVie Inc. has a 52 week low of $163.81 and a 52 week high of $244.81. The company has a quick ratio of 0.61, a current ratio of 0.74 and a debt-to-equity ratio of 44.14. The firm has a 50 day moving average of $223.40 and a 200 day moving average of $202.94.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Friday, October 31st. The company reported $1.86 earnings per share for the quarter, topping analysts’ consensus estimates of $1.77 by $0.09. AbbVie had a return on equity of 699.66% and a net margin of 6.45%.The firm had revenue of $15.78 billion during the quarter, compared to analysts’ expectations of $15.58 billion. During the same quarter last year, the firm earned $3.00 EPS. The business’s quarterly revenue was up 9.1% on a year-over-year basis. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. As a group, sell-side analysts anticipate that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be paid a $1.73 dividend. This is a boost from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date is Friday, January 16th. This represents a $6.92 dividend on an annualized basis and a yield of 3.2%. AbbVie’s dividend payout ratio (DPR) is 524.24%.

Analysts Set New Price Targets

Several research firms have recently weighed in on ABBV. Wells Fargo & Company lifted their target price on AbbVie from $240.00 to $260.00 and gave the stock an “overweight” rating in a research report on Friday, September 12th. Morgan Stanley increased their price target on AbbVie from $250.00 to $255.00 and gave the stock an “overweight” rating in a research report on Friday, August 1st. JPMorgan Chase & Co. lifted their price objective on AbbVie from $250.00 to $260.00 and gave the company an “overweight” rating in a report on Monday, November 3rd. Wall Street Zen upgraded shares of AbbVie from a “hold” rating to a “buy” rating in a report on Saturday, October 25th. Finally, UBS Group increased their price objective on shares of AbbVie from $195.00 to $220.00 and gave the company a “neutral” rating in a research note on Friday. Two research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and ten have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $236.57.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.